Patents Represented by Attorney, Agent or Law Firm Valeta Gregg
  • Modified IGF1 polypeptides with increased stability and potency
    Patent number: 7355018
    Abstract: A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: April 8, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: David J. Glass
  • Method of tumor regression with VEGF inhibitors
    Patent number: 7354578
    Abstract: Methods of regressing or inhibiting a tumor in a subject by administering an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof such that the tumor is regressed or inhibited. The method of the invention results in a reduction of tumor size and inhibition of tumor metastases. This method is particularly useful for patients suffering from bulky, metastatic cancers.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: April 8, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jessica Kandel, Jocelyn Holash, Darrell Yamashiro, Jianzhong Huang, George Yancopoulos, John Rudge
  • Use of VEGF antagonists for the treatment of malignant gliomas
    Patent number: 7354582
    Abstract: Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: April 8, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: W. K. Alfred Yung, Candelaria Gomez-Manzano, Juan Fueyo, Jesse M. Cedarbaum, Jocelyn Holash
  • Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
    Patent number: 7354581
    Abstract: Disclosed are compositions and methods for treating a disease or condition related to angiogenesis with a vascular endothelial growth factor (VEGF) inhibitor and one or more anti-hypertensive agent(s). The method of the invention is useful for preventing the development of hypertension and/or reducing hypertension in a subject treated with a VEGF inhibitor.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: April 8, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jesse M. Cedarbaum, Jocelyn Holash
  • Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)
    Patent number: 7351411
    Abstract: Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. Further included are methods of preventing anemia, increasing hematocrit levels, and increasing or stimulating erythropoietin, particularly in subjects being treated for cancer with chemotherapeutic agents and/or radiation.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: April 1, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jocelyn Holash, Jesse M. Cedarbaum, John Rudge, George D. Yancopoulos, Neil Stahl
  • Method of treatment using Tie2 ligand2
    Patent number: 7309483
    Abstract: The invention provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: December 18, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley J. Wiegand, Peter A. Campochiaro, George D. Yancopoulos
  • Use of VEGF inhibitors for treatment of eye disorders
    Patent number: 7306799
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: December 11, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley J. Wiegand, Nicholas J. Papadopoulos, George D. Yancopoulos, James P. Fandl, Thomas J. Daly
  • Use of VEGF inhibitors for treatment of eye disorders
    Patent number: 7303747
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: December 4, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley J. Wiegand, Nicholas J. Papadopoulos, George D. Yancopoulos, James P. Fandl, Thomas J. Daly
  • Methods of treating eye disorders with modified chimeric polypeptides
    Patent number: 7303746
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: December 4, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley J. Wiegand, Nicholas Papadopoulos, George D. Yancopoulos
  • Method of treating eye injury with local administration of a VEGF inhibitor
    Patent number: 7303748
    Abstract: Methods of reducing or treating angiogenesis and/or inflammation associated with eye injury in a subject in need thereof, comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or ameliorating eye injury, particularly acute or subacute corneal injury and feature local administration (for example, subconjunctival injection or eye drops).
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: December 4, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley J. Wiegand, Jingtai Cao
  • Method of treating corneal transplant rejection
    Patent number: 7300653
    Abstract: Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a subject in need thereof comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or preventing corneal transplant rejection in a human subject who is the recipient of a transplanted cornea.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: November 27, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley Wiegand, Jingtai Cao, Claus Cursiefen
  • Method of treating corneal transplant rejection in high risk keratoplasty patients
    Patent number: 7300654
    Abstract: Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a high risk subject comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or preventing corneal transplant rejection in a human subject who is the recipient of a transplanted cornea.
    Type: Grant
    Filed: January 19, 2005
    Date of Patent: November 27, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley Wiegand, Jingtai Cao, Claus Cursiefen
  • Method for generating an animal homozygous for a genetic modification
    Patent number: 7294754
    Abstract: Methods of generating modified embryos and mammals by introduction of donor cells into an early stage embryo are provided, such that the resulting embryo and animal generated therefrom has a significant or complete contribution to all tissues from the donor cells and is capable of transmitting the donor cell DNA.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: November 13, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: William Poueymirou, Thomas M. Dechiara, Wojtek Auerbach, David Frendewey, David M. Valenzuela
  • Therapeutic method for treating bone formation diseases
    Patent number: 7285532
    Abstract: Methods of treating and/or inhibiting a bone morphogenetic protein (BMP)-related disorder or condition by administering a BMP antagonist to a subject suffering from a BMP-related disorder or condition such that the BMP-related disorder or condition is treated. The method is carried out with a human noggin or a human noggin deletion mutant.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: October 23, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, Neil Stahl, David M. Valenzuela, George D. Yancopoulos
  • VEGF inhibitor polypeptides
    Patent number: 7279159
    Abstract: Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Grant
    Filed: June 29, 2004
    Date of Patent: October 9, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas J. Daly, James P. Fandl, Nicholas J. Papadopoulos
  • Morphogenic protein
    Patent number: 7241739
    Abstract: Human Cerberus proteins and related nucleic acids are provided. Included are proteins comprising a human cerberus domain having specific activity, particularly the ability to antagonize a bone morphogenic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: July 10, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, Eduardo A. Rojas, Aris N. Economides, Neil Stahl
  • Genome mutation by intron insertion into an embryonic stem cell genome
    Patent number: 7205148
    Abstract: Methods of creating mutations in genomic exons by inserting introns into the genomic exons via homologous recombination. Also, methods are provided for introducing modifications into genomic exons by inserting introns into the genomic exons via homologous recombination such that a mature mRNA transcript produced from a genomic region of the genome comprising the genomic exon does not contain the modification are provided. The methods provide for a rapid method for introducing mutations and/or modifications of any type into a mammalian cell genome.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: April 17, 2007
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, David M. Valenzuela, Samuel Davis, George Yancopoulos
  • Ion channel receptor and uses thereof
    Patent number: 7122648
    Abstract: The present invention provides for nucleic acid sequences that encode novel mammalian intracellular signaling polypeptides, designated MINC102. The invention also provides assay systems that may be used to detect and/or measure agents that bind the MINC102 gene product. The present invention also provides for diagnostic and therapeutic methods for treating muscle atrophy by inhibiting expression or activity of MINC102.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: October 17, 2006
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: David J. Glass
  • Modified ciliary neurotrophic factor (CNTF)
    Patent number: 7119066
    Abstract: Modified ciliary neurotrophic factor, methods for production and methods of use, especially in the treatment of Huntington's disease, obesity, and gestational or adult onset diabetes.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: October 10, 2006
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: James P. Fandl, Neil E. Stahl, Stanley J. Wiegand
  • Methods of modifying eukaryotic cells
    Patent number: 7105348
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: September 12, 2006
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos